Evista (chemical name: raloxifene) is a SERM approved by the U.S. Food and Drug Administration (FDA) to: 1  reduce the risk of hormone-receptor-positive breast cancer in postmenopausal women who haven't been diagnosed but are at higher-than-average risk for disease.
Types of paper ICT Express publishes original research papers in English in the fields of ICT convergence, platform technologies, communication networks, and device technologies. ICT Express accepts short-length (up to 4 pages in double columns and additional 2 pages will be allowed with over page charge (100USD/1page)) high-quality, original articles in Latex or Word format. Sample manuscript can be downloaded here.
Coverage ends at the end of the month in which your employment terminates. You may continue coverage for 18 months by submitting a continuation form to EPIC Life Insurance Company within 60 days of the coverage end date or the receipt of a continuation form, whichever is later.